Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis

Clin Rheumatol. 2002 Feb;21(1):43-5. doi: 10.1007/s100670200010.


In most patients with progressive systemic sclerosis (PSS) the oesophagus is affected. Reflux symptoms are most frequent, whilst dysphagia also occurs. Cisapride, a prokinetic agent, may enhance motility along the gastrointestinal tract. The effects of cisapride on oesophageal transit were evaluated in 12 PSS patient using a solid-phase radionuclide oesophageal transit study. Each PSS patient was given cisapride 10 mg or placebo orally three times a day in a random, double-blind, crossover fashion. The results show that cisapride does not seem to have any impact on oesophageal transit in patients with PSS.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Cisapride / administration & dosage
  • Cisapride / therapeutic use*
  • Cross-Over Studies
  • Double-Blind Method
  • Esophageal Motility Disorders / diagnostic imaging
  • Esophageal Motility Disorders / drug therapy*
  • Esophageal Motility Disorders / etiology*
  • Esophageal Motility Disorders / physiopathology
  • Esophagus / diagnostic imaging
  • Esophagus / drug effects*
  • Esophagus / physiopathology*
  • Female
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Radionuclide Imaging
  • Scleroderma, Systemic / complications*
  • Treatment Outcome


  • Gastrointestinal Agents
  • Cisapride